ArticleTranslational cancer research2021
Anti-GABAB receptor antibodies with autoimmune encephalitis in clear cell renal cell carcinoma: a case report.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Encephalitis with anti-γ-aminobutyric acid-B (GABAB) receptor antibodies is an autoimmune encephalitis, which is mainly observed with small-cell lung cancer (SCLC), thymoma, and melanoma. Here, we reported a case of clear cell renal cell carcinoma with the loss of consciousness as a first symptom, which was associated with a rare GABAB receptor antibody limbic encephalitis. A 58-year-old man with a 2-day history of stomachache and unconsciousness. Imaging studies of the head were normal. The abdominal computed tomography revealed a 3.9 cm × 3.8 cm right renal mass with contrast enhanced. Subsequent cerebrospinal fluid antibody testing was positive for anti-GABAB receptor antibodies. After 2 weeks of treatment with nutritional neurologic and immunomodulatory, the symptoms did not improve. Laparoscopic radical nephrectomy was undertaken and subsequently immunotherapy for the patient's treatment. The postoperative pathology was renal cell carcinoma (Clear cell carcinoma, WHO/ISUP grade 3, tumor size 4 cm × 3.5 cm, pT1a). The patient's conditions improved after the surgery. At the 12-month follow-up, computed tomography imaging showed no recurrence, and the patient was living independently. This case was reported to demonstrate that, when patients are presented with GABAB receptor antibody encephalitis, early evaluation of underlying malignancy including renal cell carcinoma and aggressive treatment of primary tumors provide the chances for a better outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.